Table 2 Outcomes by treatment arms—all estimates are at 5 years except if stated otherwise
DA (%) | DClo (%) | HR/OR, 95% CI | P-value | |
|---|---|---|---|---|
CR | 64 | 58 | 1.30 (0.98–1.73) | 0.07 |
CRi | 6 | 8 | ||
ORR (CR+CRi) | 71 | 66 | 1.26 (0.94–1.70) | 0.12 |
Resistant disease | 18 | 24 | 1.36 (0.97–1.91) | 0.08 |
Induction death | 11 | 11 | 0.99 (0.64–1.55) | 1.0 |
30-day mortality | 9 | 8 | 0.98 (0.61–1.57) | 0.9 |
60-day mortality | 15 | 14 | 0.96 (0.67–1.39) | 0.8 |
Overall survival | 14 | 15 | 1.04 (0.90–1.21) | 0.6 |
Relapse-free survival | 14 | 15 | 0.99 (0.83–1.19) | 0.9 |
Cumulative incidence of relapse | 78 | 72 | 0.93 (0.77–1.13) | 0.5 |
Cumulative incidence of death in CR | 8 | 13 | 1.47 (0.89–2.43) | 0.13 |
Survival post CR | 20 | 23 | 0.96 (0.80–1.16) | 0.7 |
Survival post relapse | 4 | 8 | 0.92 (0.75–1.13) | 0.4 |
